KalVista Pharmaceuticals Inc (KALV)
9.33
+0.37
(+4.13%)
USD |
NASDAQ |
Nov 21, 16:00
9.33
0.00 (0.00%)
After-Hours: 20:00
KalVista Pharmaceuticals Enterprise Value: 266.70M for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 266.70M |
| November 19, 2024 | 271.13M |
| November 18, 2024 | 283.43M |
| November 15, 2024 | 292.78M |
| November 14, 2024 | 308.04M |
| November 13, 2024 | 340.03M |
| November 12, 2024 | 350.86M |
| November 11, 2024 | 371.53M |
| November 08, 2024 | 387.28M |
| November 07, 2024 | 375.96M |
| November 06, 2024 | 387.28M |
| November 05, 2024 | 379.40M |
| November 04, 2024 | 328.32M |
| November 01, 2024 | 284.24M |
| October 31, 2024 | 269.55M |
| October 30, 2024 | 309.74M |
| October 29, 2024 | 335.24M |
| October 28, 2024 | 348.20M |
| October 25, 2024 | 330.48M |
| October 24, 2024 | 347.34M |
| October 23, 2024 | 344.75M |
| October 22, 2024 | 359.44M |
| October 21, 2024 | 358.14M |
| October 18, 2024 | 365.92M |
| October 17, 2024 | 348.20M |
| Date | Value |
|---|---|
| October 16, 2024 | 358.58M |
| October 15, 2024 | 343.45M |
| October 14, 2024 | 332.21M |
| October 11, 2024 | 328.32M |
| October 10, 2024 | 300.67M |
| October 09, 2024 | 311.47M |
| October 08, 2024 | 310.17M |
| October 07, 2024 | 313.20M |
| October 04, 2024 | 316.66M |
| October 03, 2024 | 324.43M |
| October 02, 2024 | 337.40M |
| October 01, 2024 | 317.95M |
| September 30, 2024 | 326.16M |
| September 27, 2024 | 359.01M |
| September 26, 2024 | 257.88M |
| September 25, 2024 | 234.55M |
| September 24, 2024 | 242.76M |
| September 23, 2024 | 248.38M |
| September 20, 2024 | 279.06M |
| September 19, 2024 | 301.10M |
| September 18, 2024 | 287.70M |
| September 17, 2024 | 282.52M |
| September 16, 2024 | 291.16M |
| September 13, 2024 | 307.15M |
| September 12, 2024 | 277.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-38.75M
Minimum
Oct 19 2022
968.61M
Maximum
Feb 16 2021
229.41M
Average
200.14M
Median
Oct 09 2023
Enterprise Value Benchmarks
| Nuwellis Inc | 3.781M |
| Perspective Therapeutics Inc | 150.86M |
| Electromed Inc | 233.19M |
| Xtant Medical Holdings Inc | 85.45M |
| Myomo Inc | 142.19M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.44M |
| Total Expenses (Quarterly) | 44.22M |
| EPS Diluted (Quarterly) | -0.87 |
| Earnings Yield | -38.37% |
| Normalized Earnings Yield | -17.35 |